Oculis (OCS) Scheduled to Post Quarterly Earnings on Thursday

Oculis (NASDAQ:OCS - Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, November 7th. Analysts expect Oculis to post earnings of ($0.52) per share for the quarter.

Oculis (NASDAQ:OCS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 27th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.13). Oculis had a negative net margin of 7,679.05% and a negative return on equity of 61.33%. The firm had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.28 million. On average, analysts expect Oculis to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Oculis Trading Down 1.5 %

Shares of NASDAQ:OCS traded down $0.27 on Tuesday, hitting $17.32. 69,048 shares of the company's stock were exchanged, compared to its average volume of 36,184. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.27 and a quick ratio of 5.27. The stock has a market capitalization of $701.46 million, a price-to-earnings ratio of -9.02 and a beta of -0.16. The business's 50 day simple moving average is $13.62 and its two-hundred day simple moving average is $12.47. Oculis has a 12 month low of $9.60 and a 12 month high of $18.00.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Oculis in a research report on Wednesday, October 23rd. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $29.20.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.